The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | KRAS-mutant NSCLC: CodeBreak 100 trial of sotorasib
Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the results of the Phase II CodeBreak 100 trial (NCT03600883) of sotorasib in advanced non-small cell lung cancer, highlighting the study as one of the top updates presented at WCLC 2021. Sotorasib is a a first-in-class irreversible inhibitor of KRAS-G12C and was used as a single agent to treat patients with advanced or metastatic KRAS p.G12C-mutant NSCLC. The trial gave promising progression-free survival and overall response rate data. Prof. Peled shares his thoughts on why sotorasib may be a breakthrough in lung cancer therapy. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
